Terms: = Bone cancer AND TNFRSF17, BCMA, 608, ENSG00000048462, CD269, Q02223, BCM
159 results:
1. Therapeutic potential of third-generation chimeric antigen receptor T cells targeting B cell maturation antigen for treating multiple myeloma.
Rujirachaivej P; Siriboonpiputtana T; Luangwattananun P; Yuti P; Wutti-In Y; Choomee K; Sujjitjoon J; Chareonsirisuthigul T; Rerkamnuaychoke B; Junking M; Yenchitsomanus PT
Clin Exp Med; 2024 Apr; 24(1):90. PubMed ID: 38683232
[TBL] [Abstract] [Full Text] [Related]
2. Bispecific CAR T cell therapy targeting bcma and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial.
Shi M; Wang J; Huang H; Liu D; Cheng H; Wang X; Chen W; Yan Z; Sang W; Qi K; Li D; Zhu F; Li Z; Qiao J; Wu Q; Zeng L; Fei X; Gu W; Miao Y; Xu K; Zheng J; Cao J
Nat Commun; 2024 Apr; 15(1):3371. PubMed ID: 38643278
[TBL] [Abstract] [Full Text] [Related]
3. Biomarkers of Efficacy and Safety of the Academic bcma-CART ARI0002h for the Treatment of Refractory Multiple Myeloma.
Oliver-Caldes A; Español-Rego M; Zabaleta A; González-Calle V; Navarro-Velázquez S; Inogés S; de Cerio AL; Cabañas V; López-Muñoz N; Rodríguez-Otero P; Reguera JL; Moreno DF; Martínez-Cibrian N; López-Corral L; Pérez-Amill L; Martin-Antonio B; Rosiñol L; Cid J; Tovar N; Sáez-Peñataro J; López-Parra M; Olesti E; Guillén E; Varea S; Rodríguez-Lobato LG; Battram AM; González MS; Sánchez-Salinas A; González-Navarro A; Ortiz-Maldonado V; Delgado J; Prósper F; Juan M; Martínez-López J; Moraleda JM; Mateos MV; Urbano-Ispizua Á; Paiva B; Pascal M; Fernández de Larrea C
Clin Cancer Res; 2024 May; 30(10):2085-2096. PubMed ID: 38466644
[TBL] [Abstract] [Full Text] [Related]
4. Ex Vivo Efficacy of SAR442257 Anti-CD38 Trispecific T-cell Engager in Multiple Myeloma Relapsed After Daratumumab and bcma-targeted Therapies.
Keller AL; Reiman LT; Perez de Acha O; Parzych SE; Forsberg PA; Kim PS; Bisht K; Wang H; van de Velde H; Sherbenou DW
Cancer Res Commun; 2024 Mar; 4(3):757-764. PubMed ID: 38421887
[TBL] [Abstract] [Full Text] [Related]
5. Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma.
Gagelmann N; Dima D; Merz M; Hashmi H; Ahmed N; Tovar N; Oliver-Caldés A; Stölzel F; Rathje K; Fischer L; Born P; Schäfer L; Albici AM; Schub N; Kfir-Erenfeld S; Assayag M; Asherie N; Wulf GG; Kharboutli S; Müller F; Shune L; Davis JA; Anwer F; Vucinic V; Platzbecker U; Ayuk F; Kröger N; Khouri J; Gurnari C; McGuirk J; Stepensky P; Abdallah AO; Fernández de Larrea C
J Clin Oncol; 2024 May; 42(14):1665-1675. PubMed ID: 38358946
[TBL] [Abstract] [Full Text] [Related]
6. Decomposing the rural-urban differences in depression among multimorbid older patients in India: evidence from a cross-sectional study.
Saha A; Mandal B; Muhammad T; Ali W
BMC Psychiatry; 2024 Jan; 24(1):60. PubMed ID: 38254089
[TBL] [Abstract] [Full Text] [Related]
7. Rapid anti-myeloma activity by T cells expressing an anti-bcma CAR with a human heavy-chain-only antigen-binding domain.
Mikkilineni L; Natrakul DA; Lam N; Manasanch EE; Mann J; Weissler KA; Wong N; Brudno JN; Goff SL; Yang JC; Ganaden M; Patel R; Zheng Z; Gartner JJ; Martin KR; Wang HW; Yuan CM; Lowe T; Maric I; Shao L; Jin P; Stroncek DF; Highfill SL; Rosenberg SA; Kochenderfer JN
Mol Ther; 2024 Feb; 32(2):503-526. PubMed ID: 38155568
[TBL] [Abstract] [Full Text] [Related]
8. Broadening the horizon: potential applications of CAR-T cells beyond current indications.
Karsten H; Matrisch L; Cichutek S; Fiedler W; Alsdorf W; Block A
Front Immunol; 2023; 14():1285406. PubMed ID: 38090582
[TBL] [Abstract] [Full Text] [Related]
9. Chimeric Antigen Receptor T Cell Therapy for Myeloma: Where Are We Now and What Is Needed to Move Chimeric Antigen Receptor T Cells Forward to Earlier Lines of Therapy? Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.
Anderson LD; Dhakal B; Jain T; Oluwole OO; Shah GL; Sidana S; Perales MA; Pasquini MC
Transplant Cell Ther; 2024 Jan; 30(1):17-37. PubMed ID: 37913909
[TBL] [Abstract] [Full Text] [Related]
10. bcma- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions.
Sun F; Cheng Y; Chen JR; Wanchai V; Mery DE; Xu H; Gai D; Al Hadidi S; Schinke C; Thanendrarajan S; Zangari M; van Rhee F; Tricot G; Shaughnessy JD; Zhan F
J Clin Invest; 2024 Jan; 134(1):. PubMed ID: 37883186
[TBL] [Abstract] [Full Text] [Related]
11. CD8 effector T cells enhance teclistamab response in bcma-exposed and -naïve multiple myeloma.
Firestone RS; McAvoy D; Shekarkhand T; Serrano E; Hamadeh I; Wang A; Zhu M; Qin WG; Patel D; Tan CR; Hultcrantz M; Mailankody S; Hassoun H; Shah US; Korde N; Maclachlan KH; Landau HJ; Scordo M; Shah GL; Lahoud OB; Giralt S; Murata K; Hosszu KK; Chung DJ; Lesokhin AM; Usmani SZ
Blood Adv; 2024 Apr; 8(7):1600-1611. PubMed ID: 37878808
[TBL] [Abstract] [Full Text] [Related]
12. C-reactive protein impairs immune response of CD8
Jiang J; Peng Z; Wang J; Chen M; Wan Y; Huang H; Liu Z; Wang J; Hou J
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37844994
[TBL] [Abstract] [Full Text] [Related]
13. Regulatory T cells hamper the efficacy of T-cell-engaging bispecific antibody therapy.
Casey M; Lee C; Kwok WY; Law SC; Corvino D; Gandhi MK; Harrison SJ; Nakamura K
Haematologica; 2024 Mar; 109(3):787-798. PubMed ID: 37767564
[TBL] [Abstract] [Full Text] [Related]
14. Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial.
Lin Y; Raje NS; Berdeja JG; Siegel DS; Jagannath S; Madduri D; Liedtke M; Rosenblatt J; Maus MV; Massaro M; Petrocca F; Yeri A; Finney O; Caia A; Yang Z; Martin N; Campbell TB; Rytlewski J; Fuller J; Hege K; Munshi NC; Kochenderfer JN
Nat Med; 2023 Sep; 29(9):2286-2294. PubMed ID: 37592106
[TBL] [Abstract] [Full Text] [Related]
15. IL6Myc mouse is an immunocompetent model for the development of aggressive multiple myeloma.
Pisano MD; Sun F; Cheng Y; Parashar D; Zhou V; Jing X; Sompallae R; Abrudan J; Zimmermann MT; Mathison A; Janz S; Pufall MA
Haematologica; 2023 Dec; 108(12):3372-3383. PubMed ID: 37439384
[TBL] [Abstract] [Full Text] [Related]
16. Elranatamab: a new promising BispAb in multiple myeloma treatment.
Grosicki S; Bednarczyk M; Kociszewska K
Expert Rev Anticancer Ther; 2023; 23(8):775-782. PubMed ID: 37434334
[TBL] [Abstract] [Full Text] [Related]
17. γ-Secretase inhibitor in combination with bcma chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial.
Cowan AJ; Pont MJ; Sather BD; Turtle CJ; Till BG; Libby EN; Coffey DG; Tuazon SA; Wood B; Gooley T; Wu VQ; Voutsinas J; Song X; Shadman M; Gauthier J; Chapuis AG; Milano F; Maloney DG; Riddell SR; Green DJ
Lancet Oncol; 2023 Jul; 24(7):811-822. PubMed ID: 37414012
[TBL] [Abstract] [Full Text] [Related]
18. Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer.
Newhouse R; Nelissen E; El-Shakankery KH; Rogozińska E; Bain E; Veiga S; Morrison J
Cochrane Database Syst Rev; 2023 Jul; 7(7):CD006910. PubMed ID: 37407274
[TBL] [Abstract] [Full Text] [Related]
19. Novel models by machine learning to predict prognosis of breast cancer brain metastases.
Li C; Liu M; Zhang Y; Wang Y; Li J; Sun S; Liu X; Wu H; Feng C; Yao P; Jia Y; Zhang Y; Wei X; Wu F; Du C; Zhao X; Zhang S; Qu J
J Transl Med; 2023 Jun; 21(1):404. PubMed ID: 37344847
[TBL] [Abstract] [Full Text] [Related]
20. Phase angle and body composition: A scoping review.
Martins PC; Alves Junior CAS; Silva AM; Silva DAS
Clin Nutr ESPEN; 2023 Aug; 56():237-250. PubMed ID: 37344079
[TBL] [Abstract] [Full Text] [Related]
[Next]
